Connect with us

Hi, what are you looking for?

Wednesday, Aug 17, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Mindset Pharma develops patent-pending new technology

Company announces development of novel intranasal formulation with promising efficacy

Mindset Pharma develops patent-pending new technology
Photo via Unsplash - Milad Fakurian

A drug discovery and development company dedicated to optimizing next-gen psychedelic medicines has unveiled a new technology that could forever alter the clinical psychedelic industry.

On Wednesday, Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) revealed that it had successfully developed an innovative, patent-pending intranasal formulation technology anticipated to provide enhanced central nervous system (CNS) penetration for first and future generations of psychedelic drugs.

Mindset claims to be an organization created to develop state-of-the-art medicinal assets that will assist with leveraging the breakthrough therapeutic potential of psychedelics. The outfit is currently engaged in a co-development agreement for its short-duration compounds (designated as Mindset Families 2 & 4) with the McQuade Center for Strategic Research and Development – a partner of the Japanese Otsuka Pharmaceuticals group of companies.

Additionally, the drug research professionals are currently refining a series of next-generation novel psychedelic compounds and developing a new inventive process to chemically synthesize psilocybin.

Read more: Cybin receives FDA approval for new in-human clinical trial

Read more: HAVN Life to make July appearance on renowned documentary series

Mindset’s new intranasal formulation utilizes its unique platform technology to alter the pharmacokinetic profile of active pharmaceutical elements, a uniform feature of multiple psychedelic drug candidates for the enterprise.

The proof of concept (PoC) or evidence of practicality and efficacy for Mindset’s new intranasal formulation has allegedly demonstrated superior CNS penetration compared to conventional formulations of 5-MeO-DMT administered in the past.

Mindset claims that its new unique formulation technology could potentially lessen peripheral side-effects, reduce required dose quantities and accelerate uptake and out-take from the brain. These clinical improvements will then theoretically enable more cost-efficient, safe and effective treatment.

“The intranasal formulation technology further enhances Mindset’s portfolio of complementary scientific assets. Now, the Company has a leading portfolio of next-generation NCEs, patent-pending processes to synthesize first-generation compounds efficiently and cost-effectively, and a novel intranasal delivery system to improve the overall pharmacokinetic properties of first- and second-generation psychedelic drug candidates,” said James Lanthier, CEO of Mindset Pharma.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook


Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like


Vancouver producer to supply synthetic psychedelic compounds to designated investigators and companies


Innovative new studies in the Middle East receive approval from Israeli Ministry of Health


Canadian biopharmaceutical company will receive government tax incentive for studies down under


Multi-disciplinary controlled substance company set to commence operations at Calgary facility